Skip to main content
OpenTrials

Clinical trial condition

Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)

Explore clinical trials studying Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC). Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC) trial results

Active, Not Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609

Conditions
2L+ Cervical Cancer, Advanced Solid Tumor, Female Urogenital Diseases, +27 more
Locations
  • Ascendis Pharma Investigational Site Los Angeles, California, United States
  • Ascendis Pharma Investigational Site Los Angeles, California, United States
  • Ascendis Pharma Investigational Site Springfield, Illinois, United States
  • Ascendis Pharma Investigational Site Louisville, Kentucky, United States
View all 68 locations
View Trial Details

Related conditions